SJ Robins, HB Rubins, FH Faas, EJ Schaefer, MB … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—This intention-to-treat analysis, specified as a secondary
objective in VA-HIT, determined using Cox proportional hazards models the 5-year combined
incidence of nonfatal myocardial infarction, coronary heart disease (CHD) death, or stroke ... Cited by 153 - Related articles - BL Direct - All 5 versions
- ►ahajournals.org L Tenkanen, M Manttari, V Manninen - Circulation, 1995 - Am Heart Assoc Background Coronary risk factors related to the insulin resistance syndrome tend to cluster in
the same individual. Our previous studies have shown that the dyslipidemia characteristic of
this syndrome—low HDL cholesterol and high triglyceride (TG) levels—responds well to ... Cited by 178 - Related articles - BL Direct - All 6 versions
HB Rubins, SJ Robins, D Collins, DB … - Archives of Internal …, 2002 - archinte.highwire.org You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do to make
your experience on this site better. ... Add to CiteULike Add to Connotea Add to ... Cited by 451 - Related articles - BL Direct - All 5 versions
A Tenenbaum, M Motro, EZ Fisman, D … - Archives of Internal …, 2005 - archinte.highwire.org Methods Patients who displayed at least 3 of the following 5 risk factors were considered to have
MS: (1) a fasting glucose level of 110 mg/dL (6.11 mmol/L); (2) a triglyceride level of 150
mg/dL (1.70 mmol/L); (3) a high-density lipoprotein cholesterol level less than 40 mg/dL (< ... Cited by 199 - Related articles - All 6 versions
K Pyörälä, CM Ballantyne, B Gumbiner, MW Lee, A … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Over the 5.4-year median follow-up period, simvastatin produced similar changes
in serum lipid levels in 893 patients with the metabolic syndrome and in 3,040 patients without
the metabolic syndrome. The relative risks of main end points in simvastatin-treated ... Cited by 80 - Related articles - BL Direct - All 8 versions
A Keech, RJ Simes, P Barter, J Best, R Scott, MR … - Lancet, 2005 - ncbi.nlm.nih.gov BACKGROUND: Patients with type 2 diabetes mellitus are at increased risk of cardiovascular
disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed
the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the ... Cited by 536 - Related articles - BL Direct - All 10 versions
PL Canner, CD Furberg, ML Terrin, ME McGovern - The American journal of …, 2005 - Elsevier The Coronary Drug Project, conducted during 1966 to 1974, was a randomized,
double-blind, placebo-controlled trial of 5 lipid-modifying agents in 8,341 men with previous
myocardial infarction. 1 Among the 5 drug treatment regimens, only niacin significantly ... Cited by 111 - Related articles - All 12 versions
- ►ahajournals.org CM Ballantyne, AG Olsson, TJ Cook, MF Mercuri, TR … - Circulation, 2001 - Am Heart Assoc Methods and Results— In this post hoc analysis of the Scandinavian Simvastatin Survival
Study, which enrolled patients with elevated LDL cholesterol (LDL-C) and CHD, subgroups defined
by HDL-C and triglyceride quartiles were compared to examine the influence of HDL-C ... Cited by 231 - Related articles - BL Direct - All 10 versions
MJ Chapman - Atherosclerosis, 2003 - Elsevier Objectives: To explore the therapeutic potential of fibrates to attenuate premature atherosclerosis
and cardiovascular disease in the atherogenic dyslipidemias typical of Type II diabetes, Metabolic
Syndrome, and the Type IIB (mixed) lipid phenotype; such dyslipidemias frequently ... Cited by 111 - Related articles - All 12 versions
